Antengene Receives Australian TGA Approval for ATG-018 Clinical Trial
China-based biopharma Antengene Corporation (HKG: 6996) has announced receiving approval from the Therapeutic Goods Administration...
Clinical trial approval / initiation
Jumbo Drug Bank’s JDB153 Enters Phase I Trial for Advanced Solid Tumors
Data from Fineline Cube indicates that JDB153, a potential first-in-class (FIC) small-molecule inhibitor targeting Mnk...
RemeGen’s Telitacicept Begins Global Phase III Trial for Severe SLE
China-based pharmaceutical firm RemeGen (HKG: 9995) has announced the first patient dosing in a global...
InnoCare Pharma’s ICP-189 First Dosed in China SHP2 Inhibitor Trial
Beijing InnoCare Pharma (HKG: 9969) has announced the first patient dosing in a clinical study...
InnoCare and Keymed Biosciences’ CCR8-Targeted mAb CM369 Accepted by NMPA
China-based InnoCare (HKG: 9969) and Keymed Biosciences Inc. (HKG: 2162) announced that an Investigational New...
Henlius Biotech Begins Global Phase III Trial for Denosumab Biosimilar HLX14
China-based Shanghai Henlius Biotech Inc. (HKG: 2696) has announced the first patient dosing in a...
Cellular Biomedicine Group’s C-CAR039 Receives NMPA Approval for B-Cell NHL Study
China-based Cellular Biomedicine Group Inc. (CBMG), a private company following a merger deal in February...
Yabao Pharmaceutical’s YBSW015 Gets Australian Ethical Approval for COVID-19 Trial
China-based Yabao Pharmaceutical Group Co., Ltd (SHA: 600351) has announced that it has received clinical...
Sichuan Kelun’s KL340399 Wins NMPA Approval for Solid Tumor Trials
China-based Sichuan Kelun Pharmaceutical Co., Ltd (SHE: 002422) announced receiving clinical trial approval from the...
Jiangsu Hengrui Medicine’s SHR4640 Receives NMPA Approval for Gout Trial
China-based Jiangsu Hengrui Medicine Co., Ltd (SHA: 600276) has announced receiving approval from the National...
Beijing Aosaikang’s ASKG315 Receives NMPA Approval for Solid Tumor Trial
Beijing Aosaikang Pharmaceutical Co., Ltd (SHE: 002755) announced that its clinical trial application for ASKG315,...
Alphamab Oncology Doses First Patient in Phase I Trial for PD-L1/OX40 Bispecific Antibody KN052
China-based Alphamab Oncology (HKG: 9966) has announced the dosing of the first patient in a...
Clover Biopharmaceuticals Initiates SCB-219M Clinical Study for CIT Treatment
China-based Clover Biopharmaceuticals Ltd (HKG: 2197) has announced the first subject dosing in a Phase...
Changchun High & New Technology’s Jinnamab Approved for AOSD Clinical Study by US FDA
China-based Changchun High & New Technology Industries (Group) Inc. (SHE: 000661) has announced that it...
Junshi Biosciences Receives NMPA Approval for Fourth-Generation EGFR Inhibitor WJ13404
Shanghai-based biotech Junshi Biosciences (HKG: 1877, SHA: 688180) has received approval from China’s National Medical...
Clover Biopharmaceuticals Begins Phase III Trial for COVID-19 Booster SCB-2019
China-based Clover Biopharmaceuticals Ltd (HKG: 2197) has announced the immunization of the first group of...
Kangpu Biopharmaceuticals Begins Phase IIa Trial of KPG-818 for Systemic Lupus Erythematosus
Shanghai-based Kangpu Biopharmaceuticals, Ltd has announced the first patient dosing in a multicenter, randomized, double-blind,...
Hanx Biopharmaceuticals’ HX009 Receives NMPA Clinical Trial Approval for PD-1/CD47 Bispecific Antibody
China-based Hanx Biopharmaceuticals Co., Ltd has announced that its self-developed anti PD-1/CD47 bispecific antibody drug,...